Clinical Trials Logo

Filter by:
NCT ID: NCT00494481 Completed - Clinical trials for Advanced Breast Cancer

E3 Breast Cancer Taxotere Combination

Start date: January 2006
Phase: Phase 2
Study type: Interventional

To assess the efficacy of ZD6474 in combination with docetaxel in the treatment of ABC using the progression event count methodology

NCT ID: NCT00494442 Completed - Ovarian Neoplasm Clinical Trials

Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer

ICEBERG 2
Start date: June 11, 2007
Phase: Phase 2
Study type: Interventional

The purpose of the study is to see if the drug KU 0059436 is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and for whom no curative therapeutic option exists.

NCT ID: NCT00494234 Completed - Breast Neoplasms Clinical Trials

Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer

ICEBERG 1
Start date: June 15, 2007
Phase: Phase 2
Study type: Interventional

The purpose of the study is to see if the drug KU-0059436 (olaparib) is effective and well tolerated in treating participants with measurable breast cancer gene (BRCA)1- or BRCA2-positive advanced breast cancer and for whom no curative therapeutic option exists.

NCT ID: NCT00493077 Completed - Multiple Sclerosis Clinical Trials

Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy

SAFE
Start date: May 2004
Phase: Phase 4
Study type: Interventional

This study is to find out the safety and effectiveness of Avonex (interferon-beta-1a) Therapy in patients who have developed neutralizing antibodies during previous interferon-beta treatment

NCT ID: NCT00492986 Completed - Clinical trials for Carcinoma, Renal Cell

An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma

Start date: October 2005
Phase: Phase 3
Study type: Interventional

Purpose of the study: The purpose of this study is to make sorafenib available for patients with advanced Renal Cell Carcinoma, who have failed prior systemic therapy for advanced disease (i.e. requiring second line treatment), and who do not have access to or are not eligible for other clinical trials with sorafenib and who may benefit from treatment with sorafenib. Patients will be treated orally with 400 mg bid sorafenib on a continuous basis and as a single agent. Patients may continue treatment until Disease Progression, intolerable toxicity, the patients chooses to withdraw consent or the patient is unlikely to benefit any further from treatment. Overall, participation in the study will help determine the following: - Find out if patients receiving Sorafenib will live longer - Find out if Sorafenib helps to slow the worsening of kidney cancer - Find out if Sorafenib has an effect on the tumours

NCT ID: NCT00492869 Completed - Clinical trials for Kidney Transplantation

Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation

Start date: January 2007
Phase: Phase 1/Phase 2
Study type: Interventional

Efficacy and safety of AEB071 in combination with mycophenolate acid sodium, basiliximab and steroids in preventing acute rejection after kidney transplantation.

NCT ID: NCT00492635 Completed - Clinical trials for Erectile Dysfunction

Study to Compare the Tolerability and Efficacy of Once Daily Vardenafil vs Vardenafil PRN vs Placebo in Men Immediately After Nerve-sparing Prostatectomy for Improving ED

Start date: December 2004
Phase: Phase 3
Study type: Interventional

A study to assess the efficacy of vardenafil, taken as a tablet both nightly or 'as needed' (immediately before intended sexual activity) compared to placebo, to evaluate its tolerability and if it can help in recovery of erections after a nerve sparing radical prostatectomy.

NCT ID: NCT00491829 Completed - Clinical trials for Sexual Dysfunctions, Psychological

Flibanserin Versus Placebo in Premenopausal Women With HSDD

Start date: June 2007
Phase: Phase 3
Study type: Interventional

To establish efficacy of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in 6-month treatment, vs placebo for Hypoactive Sexual Desire Disorder in premenopausal European women. To evaluate safety and tolerability of flibanserin in such patients.

NCT ID: NCT00490568 Terminated - Alzheimer's Disease Clinical Trials

Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers

Start date: August 8, 2007
Phase: Phase 3
Study type: Interventional

This is a Phase III, multicenter, open-label extension, single-group study in male and female outpatients with mild-to-moderate Alzheimer's disease (AD) who have completed either AVA102670 or AVA102672. All subjects will receive rosiglitazone extended-release (RSG XR) 4mg once daily for the first 4 weeks of the study followed by 8mg RSG XR as adjunctive therapy to their existing dose of acetylcholinesterase inhibitor. Subject participation will last until one of 5 conditions applies. After a 52-week open-label treatment phase, subjects will attend a final Follow-Up Visit 6 weeks after the end of treatment. The primary objective of this study is to evaluate the long-term safety and tolerability of RSG XR in subjects with mild-to-moderate AD who have completed either AVA102670 or AVA102672. The secondary objective of this study is to explore further the long-term efficacy of RSG XR in terms of cognitive function and overall clinical response as a function of apolipoprotein E (APOE) e4 allele status.

NCT ID: NCT00489827 Completed - Clinical trials for Coronary Artery Disease

Glutamate for Metabolic Intervention in Coronary Surgery

GLUTAMICS
Start date: October 2005
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to determine whether intravenous glutamate infusion given in association with surgery for unstable coronary artery disease can protect the heart from myocardial injury, postoperative heart failure and death.